Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Animals
Antiviral Agents
/ pharmacology
Betacoronavirus
/ drug effects
Binding Sites
/ drug effects
COVID-19
Catalytic Domain
Chlorocebus aethiops
Coronavirus 3C Proteases
Coronavirus Infections
/ drug therapy
Crystallography, X-Ray
Cysteine Endopeptidases
/ chemistry
Disease Models, Animal
High-Throughput Screening Assays
Models, Molecular
Pandemics
Pneumonia, Viral
/ drug therapy
Proline
/ analogs & derivatives
Protease Inhibitors
/ pharmacology
Pyrrolidines
/ pharmacology
RNA-Dependent RNA Polymerase
/ antagonists & inhibitors
SARS-CoV-2
Sulfonic Acids
Vero Cells
Viral Nonstructural Proteins
/ antagonists & inhibitors
Virus Replication
/ drug effects
COVID-19 Drug Treatment
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
04 09 2020
04 09 2020
Historique:
received:
23
05
2020
accepted:
22
07
2020
entrez:
5
9
2020
pubmed:
6
9
2020
medline:
24
9
2020
Statut:
epublish
Résumé
COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global public health. The coronavirus main protease (M
Identifiants
pubmed: 32887884
doi: 10.1038/s41467-020-18233-x
pii: 10.1038/s41467-020-18233-x
pmc: PMC7474075
doi:
Substances chimiques
Antiviral Agents
0
Protease Inhibitors
0
Pyrrolidines
0
Sulfonic Acids
0
Viral Nonstructural Proteins
0
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
89BT58KELH
Proline
9DLQ4CIU6V
RNA-Dependent RNA Polymerase
EC 2.7.7.48
Cysteine Endopeptidases
EC 3.4.22.-
Coronavirus 3C Proteases
EC 3.4.22.28
GC376
H1NMJ5XDG5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4417Références
Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470–473 (2020).
doi: 10.1016/S0140-6736(20)30185-9
Tan, W. et al. A novel coronavirus genome identified in a cluster of pneumonia cases — Wuhan, China 2019−2020. China CDC Weekly 2, 61–62 (2020).
doi: 10.46234/ccdcw2020.017
Li, Q. et al. Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia. New Engl. J. Med. 382, 1199–1207 (2020).
doi: 10.1056/NEJMoa2001316
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
doi: 10.1038/s41586-020-2012-7
Zhu, N. et al. A Novel Coronavirus from patients with pneumonia in China, 2019. New Engl. J. Med. 382, 727–733 (2020).
doi: 10.1056/NEJMoa2001017
Phan, L. T. et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. New Engl. J. Med. 382, 872–874 (2020).
doi: 10.1056/NEJMc2001272
Holshue, M. L. et al. First Case of 2019 Novel coronavirus in the United States. New Engl. J. Med. 382, 929–936 (2020).
doi: 10.1056/NEJMoa2001191
WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020, https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020 (2020).
WHO. World Health Organization: Coronavirus disease (COVID-2019) situation reports, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (2020).
Jiang, S. et al. A distinct name is needed for the new coronavirus. Lancet 395, 949 (2020).
doi: 10.1016/S0140-6736(20)30419-0
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020).
Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
doi: 10.1016/S0140-6736(20)30251-8
Guan, W.-j et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl. J. Med. 382, 1708–1720 (2020).
doi: 10.1056/NEJMoa2002032
Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).
doi: 10.1016/S0140-6736(20)30566-3
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020).
doi: 10.1016/j.cell.2020.02.058
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
doi: 10.1126/science.abb2507
Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444–1448 (2020).
doi: 10.1126/science.abb2762
Wang, Q. et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181, 894–904.e9 (2020).
doi: 10.1016/j.cell.2020.03.045
Dong, L., Hu, S. & Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther. 14, 58–60 (2020).
doi: 10.5582/ddt.2020.01012
Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020).
doi: 10.1038/s41422-020-0282-0
Lu, H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends 14, 69–71 (2020).
doi: 10.5582/bst.2020.01020
Ni, L., Zhou, L., Zhou, M., Zhao, J. & Wang, D. W. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front. Med. 14, 210–214 (2020).
doi: 10.1007/s11684-020-0757-x
Agbowuro, A. A., Huston, W. M., Gamble, A. B. & Tyndall, J. D. A. Proteases and protease inhibitors in infectious diseases. Med. Res. Rev. 38, 1295–1331 (2018).
doi: 10.1002/med.21475
Cao, B. et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New Engl. J. Med. 382, 1787–1799 (2020).
doi: 10.1056/NEJMoa2001282
Xue, X. et al. Production of authentic SARS-CoV Mpro with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction. J. Mol. Biol. 366, 965–975 (2007).
doi: 10.1016/j.jmb.2006.11.073
Jin, Z. et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature 582, 289–293 (2020).
Prongay, A. J. et al. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. J. Med. Chem. 50, 2310–2318 (2007).
doi: 10.1021/jm060173k
Malcolm, B. A. et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother. 50, 1013–1020 (2006).
doi: 10.1128/AAC.50.3.1013-1020.2006
Kim, Y. et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. 86, 11754–11762 (2012).
doi: 10.1128/JVI.01348-12
Pedersen, N. C. et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J. Feline Med. Surg. 20, 378–392 (2018).
doi: 10.1177/1098612X17729626
Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 368, 409–412 (2020).
pubmed: 32198291
pmcid: 7164518
Dai, W. et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331–1335 (2020).
Lin, C., Kwong, A. D. & Perni, R. B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets 6, 3–16 (2006).
doi: 10.2174/187152606776056706
Cummings, M. D. et al. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew. Chem. Int. Ed. 49, 1652–1655 (2010).
doi: 10.1002/anie.200906696
Soumana, D. I., Ali, A. & Schiffer, C. A. Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem. Biol. 9, 2485–2490 (2014).
doi: 10.1021/cb5006118
Romano, K. P. et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 8, e1002832 (2012).
doi: 10.1371/journal.ppat.1002832
Pedersen, N. C. et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J. Feline Med. Surg. 20, 378–392 (2017).
doi: 10.1177/1098612X17729626
Kim, Y. et al. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog. 12, e1005531 (2016).
doi: 10.1371/journal.ppat.1005531
Yang, H. et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 3, e324 (2005).
doi: 10.1371/journal.pbio.0030324
Yang, H. et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl Acad. Sci. USA 100, 13190–13195 (2003).
doi: 10.1073/pnas.1835675100
Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326 (1997).
doi: 10.1016/S0076-6879(97)76066-X
Read, R. J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. D Biol. Crystallogr. 57, 1373–1382 (2001).
doi: 10.1107/S0907444901012471
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
doi: 10.1107/S0907444904019158
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).
doi: 10.1107/S0907444909052925
Williams, C. J. et al. MolProbity: more and better reference data for improved all-atom structure validation. Protein Sci. 27, 293–315 (2018).
doi: 10.1002/pro.3330